Montelukast Amarox

Montelukast, the active ingredient in Montelukast Amarox, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is indicated for the management of asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards, provides regulatory‑approved batches, and offers reliable logistics to meet global demand for this essential respiratory medication effectively.

Montelukast is a leukotriene receptor antagonist used to manage respiratory and allergic conditions.

- Asthma: reduces frequency of symptoms, improves lung function, and decreases need for rescue inhalers. - Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate discomfort. - Abdominal pain: occasional stomach upset. - Cough: transient irritation. - Nausea: occasional queasiness. - Diarrhea: loose stools. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, angioedema. - Neuropsychiatric events: mood changes, depression, suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin reaction. - Anaphylaxis: rare life‑threatening hypersensitivity.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Pregnancy: consult a healthcare provider as safety data are limited. - Breastfeeding: use with caution; monitor infant for adverse effects. - Hepatic impairment: consider dose adjustment or close monitoring. - Concomitant asthma therapy: do not discontinue other controller medications without medical advice. - Neuropsychiatric events: monitor patients for mood changes or suicidal ideation. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Rifampin: induces metabolism, lowering montelukast plasma levels. - Phenobarbital: may decrease therapeutic effect through enzyme induction. - Ketoconazole: can increase montelukast concentrations, raising risk of side effects.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect; monitor INR. - Beta‑agonists: additive bronchodilation may occur; observe respiratory response. - Antidepressants: monitor for enhanced neuropsychiatric symptoms.